- cafead   Apr 05, 2023 at 10:32: AM
via AstraZeneca touted positive data for its Lynparza-Imfinzi blockbuster combo today with a high-level analysis from its DUO-O Phase III trial, in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutations.
article source
article source